Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AlzeCure Pharma ABFRA:AC6 -3.57%35 EV-to-EBITDA is 26.43 as of Sep. 21, 2026, which is 11% above its 10-year median of 23.72. GuruFocus rates FRA:AC6 with a GF Score™ of 35/100. The stock has 5 warning signs investors should review. Among 430 Biotechnology companies, AlzeCure Pharma AB ranks worse than 71.4% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, AlzeCure Pharma AB's enterprise value is €77.87 Mil.
AlzeCure Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €2.95 Mil. Therefore, AlzeCure Pharma AB's EV-to-EBITDA for today is 26.43.
The historical rank and industry rank for AlzeCure Pharma AB's EV-to-EBITDA or its related term are showing as below:
FRA:AC6'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 21.22 Med: 23.72 Max: 28.87
Current: 27.24
During the past 9 years, the highest EV-to-EBITDA of AlzeCure Pharma AB was 28.87. The lowest was 21.22. And the median was 23.72.
FRA:AC6's EV-to-EBITDA is ranked worse than 71.4% of 430
companies
in the Biotechnology industry
Industry Median: 13.015
vs FRA:AC6: 27.24
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
AlzeCure Pharma AB (FRA:AC6) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AlzeCure Pharma AB's PE Ratio (TTM) for today is calculated as:
AlzeCure Pharma AB's share price for today is €0.648.
AlzeCure Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.019.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for AlzeCure Pharma AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AC6 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, AlzeCure Pharma AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AlzeCure Pharma AB EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AlzeCure Pharma AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where AlzeCure Pharma AB's EV-to-EBITDA falls into.
AlzeCure Pharma AB's current Enterprise Value is €77.87 Mil.
AlzeCure Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AlzeCure Pharma AB (FRA:AC6) has a EV-to-EBITDA of 26.43 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AlzeCure Pharma AB. This is 11% above median its historical median of 23.72. Over the past decade, AlzeCure Pharma AB's EV-to-EBITDA has ranged from 21.22 to 28.87. According to the industry distribution chart, AlzeCure Pharma AB ranks #307 out of 430 companies in the Biotechnology industry, placing it in the top 71.4%.
Is AlzeCure Pharma AB's EV-to-EBITDA too high?
AlzeCure Pharma AB's current EV-to-EBITDA of 26.43 is 11% above median its 10-year median of 23.72. Over the past 10 years, this metric has ranged from a low of 21.22 to a high of 28.87. The Biotechnology industry median EV-to-EBITDA is 13.02. AlzeCure Pharma AB's value of 26.43 is 103.1% above this industry median. Based on the distribution chart, AlzeCure Pharma AB ranks #307 out of 430 companies in the Biotechnology industry, which is below the industry midpoint. Overall, AlzeCure Pharma AB has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does AlzeCure Pharma AB's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, AlzeCure Pharma AB ranks #307 out of 430 companies for EV-to-EBITDA. This places AlzeCure Pharma AB in the lower half of its industry. The industry median EV-to-EBITDA is 13.02. AlzeCure Pharma AB's value of 26.43 is 103.1% above this benchmark. Historically, AlzeCure Pharma AB's own EV-to-EBITDA has ranged from 21.22 to 28.87 over the past decade. While the company's 10-year median is 23.72 vs. the industry median of 13.02, AlzeCure Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.02, based on 430 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AlzeCure Pharma AB's current EV-to-EBITDA of 26.43 is 103.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AlzeCure Pharma AB. For the Biotechnology industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AlzeCure Pharma AB's current EV-to-EBITDA is 26.43, which is 11% above median its own 10-year median of 23.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AlzeCure Pharma AB stock overvalued right now?
AlzeCure Pharma AB (FRA:AC6) has a current EV-to-EBITDA of 26.43. The current EV-to-EBITDA is 26.43, which is 11% above median its 10-year median of 23.72 and 103.1% above the Biotechnology industry median of 13.02. AlzeCure Pharma AB's overall GF Score™ is 35/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For AlzeCure Pharma AB (FRA:AC6), the current EV-to-EBITDA is 26.43 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms, NeuroRestore, Alzstatin, and Painless. The company's drug candidates include: ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatment of severe pain in conditions such as osteoarthritis.
35GF Score
Get the complete analysis for FRA:AC6
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AC6 has been successfully added to your 
